# GLP-1 medication use and evolving therapeutic findings > Live situation record from CLSTR: https://clstr.news/situations/glp-1-medication-use-and-pediatric-implications > Updated: 2026-09-12T02:57:22.000Z. Sources: 18. Developments: 2. GLP-1 receptor agonists, including semaglutide and tirzepatide, are seeing increased use for the management of type 2 diabetes and obesity. While these medications provide benefits for glycemic control and weight loss, they are linked to gastrointestinal side effects such as nausea and vomiting, as well as rarer risks like pancreatitis. Recent research suggests these drugs offer therapeutic benefits beyond weight loss. Clinical data indicates they can provide significant cardiovascular protection, reducing the risk of major adverse events like heart attacks and strokes by approximately 20% in high-risk populations. Evidence also suggests they may reduce the severity of obstructive sleep apnea in adults linked to obesity. New findings indicate these medications may also decrease the frequency of asthma and COPD exacerbations by up to 40 percent. Furthermore, studies have observed potential anti-aging effects. Preclinical research from the University of California, Berkeley, involving elderly mice, showed semaglutide extended median lifespans by approximately 12 percent and improved cognitive function, muscle performance, and tissue repair capabilities. There remains a notable trend toward pediatric use, with early trials showing significant BMI reduction in children with obesity. However, medical professionals have identified new potential risks, including 15 cases of Wernicke encephalopathy, a serious brain disorder linked to vitamin B1 deficiency. Economically, the surge in demand is impacting the retail sector, with pharmacy units in major grocery chains like Loblaw reporting significant sales growth. ## Claims - Semaglutide increased the median lifespan of elderly female mice by approximately 12 percent. (corroborated by 4 sources) - Semaglutide treatment in mice showed improvements in muscle function, cognitive performance, and spatial memory. (corroborated by 3 sources) - In a clinical trial, 40.4 percent of children aged 6 to 12 treated with semaglutide were no longer classified as obese after 68 weeks. (corroborated by 2 sources) - Researchers identified 15 cases of Wernicke encephalopathy, a potentially fatal brain disorder caused by vitamin B1 deficiency, in individuals using GLP-1 agonists. (single source) - The SELECT trial found that semaglutide reduced the risk of major adverse cardiovascular events by 20% in overweight or obese adults with pre-existing cardiovascular disease. (single source) - Novo Nordisk reported that the Wegovy pill is its strongest GLP-1 volume launch to date in the United States. (single source) - Observational data from the UK suggests semaglutide can reduce the occurrence of asthma attacks by approximately 40 percent. (single source) - Loblaw reported a roughly 40 percent surge in GLP-1 sales over its last two quarters. (single source) ## Timeline ### 2026-09-12: GLP-1 medications show expanded therapeutic benefits and anti-aging potential GLP-1 drugs like semaglutide are showing expanded benefits, including potential anti-aging effects in mice, cardiovascular protection, and reduced respiratory issues, alongside rising commercial demand. 18 sources. https://clstr.news/cluster/glp-1-medications-see-rising-use-in-obesity-and-diabetes-treatment ### 2026-08-18: GLP-1 medication use raises concerns for parents regarding child nutrition Parents using GLP-1 medications face concerns regarding their children's body image and nutrition. Experts advise open communication to prevent eating disorders and misconceptions. 6 sources. https://clstr.news/cluster/glp-1-medication-use-raises-concerns-for-parents-regarding-child-nutrition --- Cite as: GLP-1 medication use and evolving therapeutic findings. CLSTR, https://clstr.news/situations/glp-1-medication-use-and-pediatric-implications